SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial.
Barbara H McGovernChristopher B FordMatthew R HennDarrell S PardiSahil KhannaElizabeth L HohmannEdward J O'BrienChristopher A DesjardinsPatricia BernardoJennifer R WortmanMary-Jane LombardoKevin D LitcofskyJonathan A WinklerChristopher W J McChalicherSunny S LiAmelia D TomlinsonMadhumitha NandakumarDavid N CookRoger J PomerantzJohn G AuninšMichele TrucksisPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021)
NCT02437487, https://clinicaltrials.gov/ct2/show/NCT02437487?term=SER-109&draw= 2&rank=4.